FTC's Prevagen Complaint Revived: Court Says 'Deceptive' Ad Allegation Plausible
Executive Summary
District court erred in dismissing FTC complaint that Prevagen marketer Quincy Biosciences used deceptive representations in ads, Second Circuit says in long-awaited order. FTC and New York attorney general, along with advocacy group TINA, criticize Quincy's post hoc data analyses finding "false positives."
You may also be interested in...
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
FTC’s Monetary Relief Claims Dismissed In Prevagen Fraud Case; Supreme Court Decision Cited
The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a federal judge in New York, who cites recent Supreme Court decision gutting the agency's long-favored mechanism for collecting monetary penalties under the FTC Act.
Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement
Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.